SIRION Biotech Participates in Gene Therapy Expert Panel Discussion at the Piper Jaffray GenomeRx Symposium

(PresseBox) - SIRION Biotech GmbH enables its customers to advance the field of gene therapy through multiple proprietary viral vector platforms. The company today announced that its Chief Technology Officer, Christian Thirion, Ph.D., yesterday participated on a panel with leading gene therapy industry experts covering the regulatory needs in clinical development at the Piper Jaffray GenomeRx Symposium at the Yale Club in New York City.
"It's an honor to be part of such distinguished panel as the field of gene therapy continues to deliver important advances to patients. At SIRION, we see our role evolving as critical viral vector supplier across multiple proprietary platforms, said Chrisitian Thirion, Ph.D., Chief Technology Officer."

Started in 2006 in Munich, SIRION Biotech today has partnered with more than 100 clients in 300 projects across the globe. The company has raised more than $8M in venture financing from European funds since it's inception. SIRION Biotech's customers include leading academic and pharmaceutical and biotechnology companies.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: PresseBox
Datum: 24.06.2014 - 15:00 Uhr
Sprache: Deutsch
News-ID 333309
Anzahl Zeichen: 1124

contact information:
Town:

Martinsried

Kategorie:

Handcrafts

Diese Pressemitteilung wurde bisher 437 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"SIRION Biotech Participates in Gene Therapy Expert Panel Discussion at the Piper Jaffray GenomeRx Symposium"
steht unter der journalistisch-redaktionellen Verantwortung von

SIRION BIOTECH GmbH (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

SIRION Biotech Granted CIR accreditation by French Ministry of Higher Education, ...

The French Ministry of Higher Education, Research and Innovation have granted SIRION Biotech a 3-year CIR (Crédit Impôt Recherche) accreditation lasting until end of 2023. As a result, SIRION Biotech GmbH is now on a list of experts accessible on t ...

Next-generation AAV gene therapy from joined German forces ...

The viral vector specialist SIRION Biotech GmbH today announces the signing of a preferred partnership agreement with Heidelberg University Hospital and AAV pioneer Prof. Dirk Grimm. This strategic alliance will enable both partners to offer engineer ...

SIRION Biotech and Vibalogics partner to offer complete Adeno-Associated Virus ( ...

SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene therapy companies for a start-to-finish Adeno-Associated Virus (AAV) service. The new service offering, which will be available f ...

Alle Meldungen von SIRION BIOTECH GmbH